George Scangos made a surprising shift when the former Biogen CEO left the world of big biotech to lead an infectious disease-focused start-up. Vir Biotechnology Inc. emerged in early 2017 with $150m and quickly brought its fundraising total later that year to more than $500m. The company went public late last year and Vir’s participation in the search for a coronavirus treatment has thrust the company into the spotlight in the last month, and elevated Scangos’s profile once again since he’s also leading BIO’s outreach to biotech firms to help get their coronavirus ideas from concept to clinical trials.
Vir Advances Antibodies Against COVID-19, CEO Scangos Leads BIO’s Coronavirus Outreach
Scrip talked to George Scangos about his dual roles in the pandemic response, helming Vir as the company tests antibody and siRNA approaches while working with BIO to facilitate coronavirus collaborations.
More from COVID-19
• By
Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.
• By
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
• By
Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.
• By
Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.
More from Scrip
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.